Cardiology is one of the highest-velocity specialties in medicine. Major trials reported at ACC, AHA, and ESC meetings routinely change standard of care within months of publication. This guide covers practical strategies for cardiologists to stay genuinely current without reading every paper in every journal.
Cardiovascular medicine is served by more high-quality journals than almost any other specialty. The core publications that drive practice change include the New England Journal of Medicine, JAMA Cardiology, Circulation, the Journal of the American College of Cardiology (JACC), and the European Heart Journal. Each publishes weekly or biweekly, meaning a cardiologist attempting to read all five comprehensively would encounter several hundred articles per month.
The practical answer is not to read all of them — it is to have a reliable system that surfaces the subset that changes what you do in clinic tomorrow.
The most important literature for a practicing cardiologist falls into four categories:
The major cardiology meetings — ACC Annual Scientific Sessions (March), ESC Congress (August/September), and AHA Scientific Sessions (November) — are where most landmark trials are first presented. Rapid publication in NEJM or JACC typically accompanies or immediately follows the presentation. Building a habit of following the late-breaking trial sessions from these meetings, even via summaries and press releases, captures the highest-impact cardiology evidence efficiently.
Practical tip: Set up a calendar reminder the week before each major cardiology conference. Read the late-breaking trials session summary — typically published same-day on ACC.org, ESC website, and NEJM — rather than waiting for the papers to appear in your journal alerts weeks later.
A general cardiologist seeing a broad outpatient practice needs breadth across arrhythmia, coronary disease, heart failure, valvular disease, and prevention. A subspecialist can go deeper in one domain. The reading strategy should match the scope:
The cardiovascular outcome trials for SGLT2 inhibitors — EMPA-REG OUTCOME (2015), CANVAS (2017), DECLARE-TIMI 58 (2018), DAPA-HF (2019), EMPEROR-Reduced (2020), EMPEROR-Preserved (2021), DELIVER (2022) — fundamentally changed the management of both type 2 diabetes and heart failure across ejection fraction subtypes over a seven-year period. A cardiologist who read the trials as they emerged integrated this gradually and naturally. One who did not has a substantial update to make all at once — with patients on suboptimal therapy in the meantime.
This is the cost of falling behind in a high-velocity field: not embarrassment, but patients who do not receive evidence-based care.
| Format | Best use | Time investment |
|---|---|---|
| Abstract only | Initial screening of new publications | 90 seconds per paper |
| Structured summary | Papers with potential practice implications | 3–5 minutes |
| Full text | Direct implications for your patient panel | 20–30 minutes |
| Conference summary | Late-breaking trial capture | 10–15 minutes per meeting |
| AI-curated digest | Weekly discovery — what did I miss? | 15 minutes per week |
The American College of Cardiology offers approximately 200 CME opportunities annually through ACC.org. The most efficient are self-assessment programs (SAPs) tied to specific topic areas, which award significant credits for reading curated content and completing assessments. Cardiology board recertification requires 100 CME credits per cycle, 20 of which must come from self-assessment activities. Building CME acquisition into your reading habit rather than treating it as a separate annual chore is the most efficient approach.
MDInformed curates the five most clinically relevant papers from 35 million publications and delivers them as a structured digest — free forever.
Join the waitlist →